Form 4: BioCryst Pharmaceuticals CEO Jon P. Stonehouse Increases Stake in Company

BioCryst Pharmaceuticals' CEO, Jon P. Stonehouse, recently acquired 30,000 shares of common stock, increasing his direct holdings.

Summary

• On May 13, 2024, Jon P. Stonehouse, the President and CEO of BioCryst Pharmaceuticals, purchased 30,000 shares of the company's common stock at a weighted average price of $5.55.
• The purchases were made in multiple transactions with prices ranging from $5.34 to $5.68.
• Following this transaction, Stonehouse directly owns 1,127,770 shares of BioCryst Pharmaceuticals.
• He also has indirect ownership of 20,000 shares held by his wife as co-trustee of the Caroline Stonehouse Irrevocable Trust and another 20,000 shares held by his wife as co-trustee of the Samuel Stonehouse Irrevocable Trust.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the CEO's increased investment in the company, which can be interpreted as a sign of confidence. However, it's a single transaction and doesn't provide a comprehensive view of the company's overall health.

Positives

• The CEO's purchase of shares may signal confidence in the company's future prospects.

Industry Context

Insider buying is often seen as a positive sign, suggesting that a company's leadership believes the stock is undervalued or that the company is expected to perform well in the future. Investors often monitor Form 4 filings to gain insights into the actions of company insiders.

Stakeholder Impact

• Shareholders may view the CEO's purchase as a positive signal.
• The increased stake aligns the CEO's interests more closely with those of other shareholders.

Key Dates